This on-demand course is designed to empower you with the knowledge and skills needed to deliver optimal care for your patients with non-small cell lung cancer (NSCLC) by deepening your understanding of crucial topics such as:
The importance of biomarker testing for treatment response prediction
The pivotal role of PD-1/PD-L1 inhibitors in both neoadjuvant and adjuvant settings
The practical application of this knowledge with a patient-centered approach
Provided by NCCN in partnership with The France Foundation.
Accreditation:
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, PAs, and other health care professionals.
Fee Information:
There is no fee for this educational program for registrants.
Faculty Contributors:
Debora Bruno, MD, MS Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Matthew Gubens, MD, MS UCSF Helen Diller Family Comprehensive Cancer Center
Sandip Patel, MD UC San Diego Moores Cancer Center
Beth Sandy, MSN, CRNP Abramson Cancer Center at the University of Pennsylvania
Supporters:
This activity is supported by an educational grant from Genentech, a member of the Roche Group. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
